Syndax Pharmaceuticals Inc — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Syndax announced two new pipeline programs: SNDX-4321, a novel allosteric EGFR inhibitor (licensed from Dana-Farber, IND planned by end-2026, Phase 1 in 2027) for EGFRm NSCLC; and SNDX-62122, an internally developed next-generation menin inhibitor (IND and Phase 1 planned for 2027) for myelofibrosis, to be de-risked by a revumenib proof-of-principle trial initiating 4Q26. Both programs target high unmet-need indications with preclinical support. Syndax also highlighted progress on late-stage programs: axatilimab Phase 2 IPF data expected 4Q26, revumenib continuing advancement in acute leukemia.
Why this rating
Pipeline expansion is meaningful but early-stage (preclinical to Phase 1 entry); both molecules address real unmet needs in significant markets (NSCLC, MF), but represent future optionality rather than near-term revenue drivers. Positive signal, moderate relative materiality given company's $799M market cap and current cash position.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.